Endothelin-1 and Nitric Oxide Synthase: Role in Glaucoma
Principal Investigator
Ganesh Prasanna, PhD
University of North Texas Health Science Center
Fort Worth, TX, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$60,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000006
Summary
Endothelin-1 (ET-1) is a small peptide molecule that causes blood vessels to constrict. It is elevated in the aqueous humor of people with primary open angle glaucoma and in the blood plasma of people with normal tension glaucoma. Chronic low-dose administration of the peptide to primates produces optic nerve damage that mirrors the damage found in glaucoma. ET-1 may also regulate another vessel-constricting molecule called nitric oxide (NO). The excess production of NO, through enzymes called NO synthases (NOS), in ocular cells also causes optic nerve damage. It has been found that in rats with glaucoma, inhibitors of the NOS-2 enzyme prevent damage to the retinal ganglion cells. In earlier research, Dr. Prasanna found evidence that ET-1 increases the amount of NOS-2 in human pigmented ciliary epithelial cells, and is now utilizing the rat model of glaucoma to examine the role of ET-1 in regulating NOS-2 gene expression. The knowledge gained from this study could help provide a basis for the use of molecules that inhibit the activity of ET-1 as a possible treatment of glaucoma.
Related Grants
National Glaucoma Research
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester